A SYSTEMATIC review investigating the impact of glucagon-like peptide-1 receptor agonists on alcohol consumption has yielded ...

The Biden administration is proposing Medicare and Medicaid coverage for glucagon-like peptide 1 receptor agonist (GLP-1 RA) ...

Takers of GLP-1 are reportedly going on a "holiday pause" to enjoy meal centric family celebrations. Here, an MD breaks down ...

There has been a lot of conversation lately about if new weight loss drugs like Wegovy and Mounjaro should be covered by ...

It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.

Semaglutide and liraglutide are associated with a reduced risk for hospitalization due to alcohol use disorder (AUD).

Researchers evaluate the effects of glucagon-like peptide-1 receptor agonists on kidney and cardiovascular outcomes.

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

A new study suggests that 40% of American adults have conditions that could benefit from semaglutide treatment.

Strata Decision Technology data finds the number of bariatric surgeries in the Chicago area may have fallen by more than half ...

The Biden administration plans to require Medicare and Medicaid to offer coverage of weight loss medications for people seeking obesity treatment.The new rule, which was proposed by the administration ...